Romano Brothers & Co’s Gilead Sciences GILD Stock Holding History

Romano Brothers & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Buy	15,921 +4	+0%	+$527	0.2%	120
2026 Q1	$2.22M	Hold	15,917	–	–	0.25%	107
2025 Q4	$1.95M	Sell	15,917 -1,580	-9%	-$192K	0.22%	111
2025 Q3	$1.94M	Sell	17,497 -200	-1%	-$22.7K	0.22%	113
2025 Q2	$1.96M	Sell	17,697 -100	-0.6%	-$10.6K	0.24%	108
2025 Q1	$1.99M	Sell	17,797 -175	-1%	-$18.1K	0.26%	104
2024 Q4	$1.66M	Hold	17,972	–	–	0.21%	121
2024 Q3	$1.51M	Hold	17,972	–	–	0.19%	129
2024 Q2	$1.23M	Sell	17,972 -250	-1%	-$16.7K	0.17%	134
2024 Q1	$1.33M	Sell	18,222 -425	-2%	-$32.7K	0.18%	133
2023 Q4	$1.51M	Sell	18,647 -65	-0.3%	-$5.06K	0.22%	118
2023 Q3	$1.4M	Sell	18,712 -2,829	-13%	-$218K	0.22%	118
2023 Q2	$1.66M	Sell	21,541 -550	-2%	-$43.9K	0.25%	111
2023 Q1	$1.83M	Sell	22,091 -350	-2%	-$29K	0.28%	104
2022 Q4	$1.93M	Sell	22,441 -1,921	-8%	-$152K	0.29%	100
2022 Q3	$1.51M	Buy	+24,362	New	+$1.54M	0.24%	109

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Romano Brothers & Co's GILD Position: Q2 2026 in Review

Romano Brothers & Co increased its Gilead Sciences (GILD) stake by 0.03% in Q2 2026, buying an estimated $527 and bringing the position to 15,921 shares worth $2.01M. The position accounts for 0.2% of the portfolio, ranked #120.

Romano Brothers & Co first reported a position in GILD in Q3 2022 and has held it in 16 quarters since. The position peaked at $2.22M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Romano Brothers & Co held 15,921 shares of Gilead Sciences worth $2.01M as of Q2 2026.
Romano Brothers & Co bought 4 Gilead Sciences shares in Q2 2026, an estimated $527.
Gilead Sciences made up 0.2% of Romano Brothers & Co's portfolio in Q2 2026, its #120 holding.
Romano Brothers & Co first reported a position in Gilead Sciences in Q3 2022 and has held it in 16 quarters since.
Romano Brothers & Co's Gilead Sciences position peaked at $2.22M in Q1 2026.
2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Romano Brothers & Co's 13F filing for Q2 2026, filed 22 Jul 2026.